4.7 Review

Efficacy and Safety of Dry Powder Antibiotics: A Narrative Review

Journal

JOURNAL OF CLINICAL MEDICINE
Volume 12, Issue 10, Pages -

Publisher

MDPI
DOI: 10.3390/jcm12103577

Keywords

antibiotics; inhalation drug; Pseudomonas aeruginosa; chronic bronchial infection; bronchiectasis; cystic fibrosis; dry powder antibiotics

Ask authors/readers for more resources

The use of inhaled antibiotics has expanded beyond cystic fibrosis patients to include non-CF bronchiectasis or chronic obstructive pulmonary disease patients. Inhaled antibiotics provide high concentrations at the site of infection, enhancing their effectiveness and allowing for long-term administration. New formulations of inhaled dry powder antibiotics offer advantages such as faster preparation and administration, as well as eliminating the need for cleaning nebulization equipment.
The use of inhaled antibiotics was initially almost exclusively confined to patients with cystic fibrosis (CF). However, it has been extended in recent decades to patients with non-CF bronchiectasis or chronic obstructive pulmonary disease who present with chronic bronchial infection by potentially pathogenic microorganisms. Inhaled antibiotics reach high concentrations in the area of infection, which enhances their effect and enables their long-term administration to defeat the most resistant infections, while minimizing possible adverse effects. New formulations of inhaled dry powder antibiotics have been developed, providing, among other advantages, faster preparation and administration of the drug, as well as avoiding the requirement to clean nebulization equipment. In this review, we analyze the advantages and disadvantages of the different types of devices that allow the inhalation of antibiotics, especially dry powder inhalers. We describe their general characteristics, the different inhalers on the market and the proper way to use them. We analyze the factors that influence the way in which the dry powder drug reaches the lower airways, as well as aspects of microbiological effectiveness and risks of resistance development. We review the scientific evidence on the use of colistin and tobramycin with this type of device, both in patients with CF and with non-CF bronchiectasis. Finally, we discuss the literature on the development of new dry powder antibiotics.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available